PIK3CA mutations are identified in 10–15% of metastatic CRC (mCRC) patients, and a recent meta-analysis suggested their association with proximal tumor location, mucinous histological subtype, and co-occurrence with KRAS mutations. The gene discussed is KRAS; the disease is neoplasm.